摘要
目的探讨2型糖尿病患者应用厄贝沙坦治疗前后其血浆TXA2/PGI2的变化,并分析其与患者尿微量白蛋白水平之间的关系。方法研究中共收入112例2型糖尿病患者,随机分入对照组及治疗组,以ELISA法检测其血浆中TXA2与PGI2的水平,同时对研究对象的尿微量白蛋白水平进行检测,分析治疗前后患者尿微量白蛋白水平的变化。结果治疗组患者在接受4周厄贝沙坦治疗后其血浆TXA2水平(319.65±38.76)pg/mL显著低于治疗前(342.12±48.22)pg/mL(P<0.01),而PGI2水平(40.04±4.95)pg/mL则显著高于治疗前(32.13±4.47)pg/mL(P<0.01),治疗组患者尿微量白蛋白水平较治疗前有显著下降[治疗后(36.42±4.95)mg/Lv.s.治疗前(43.99±11.27)mg/L,P<0.01];对照组中患者的TXA2/PGI2及尿微量白蛋白水平在接受治疗前后差异无统计学意义。结论2型糖尿病患者接受厄贝沙坦治疗后血浆TXA2/PGI2水平产生变化,同时尿微量白蛋白水平下降,提示TXA2/PGI2可能参与糖尿病肾病发展过程,而厄贝沙坦则可能阻断此过程并产生肾保护作用。
Objective The study was set to explore the changes of plasma levels of TXA2 /PGI2 and microalbuminuria in type 2 diabetic patients treated with Irbesartan.Methods 112 cases of type 2 diabetic patients were enrolled into the study.They were randomly divided into controlled group and treatment group.The plasma levels of TXA2 and PGI2 was detected by ELISA.The studied objects clinical data and the level of microalbuminuria were collected.Results In treatment group the patients plasma level of TXA2（319.65±38.76）pg/mL was significant lower than that of the initialization data[ （342.12±48.22）pg/mL,P〈0.01 ] after 4-week treatment of Irbesartan. And plasma level of PGI2 was significantly raised after treatment [after treatment （40.04±4.95）pg/mL v.s. before treatment （32.13±4.47）pg/mL,P〈0.01]. Patients＇ mieroalbuminuria level was significant lower after 4-week treatment [after treatment （36.42±4.95）mg/L v.s. before treatment （43.99±11.27）mg/L]. In the controlled group there were no significant changes in TXA2/PGI2 and microalbuminuria level after receiving treatment without Irbesartan. Conclusion Type 2 diabetic patients＇ plasma level of TXA2/PGI2 shows changes after Irbesartan treatment with relief in mieroalbuminuria level. The TXA2/PGI2 may take part in the pathogenesis of diabetic nephropathy. Irbesartan may be able to block the process.
出处
《热带医学杂志》
CAS
2009年第10期1169-1170,1181,共3页
Journal of Tropical Medicine
基金
广东省中医药局建设中医药强省科研课题(No.2007230)
关键词
糖尿病
糖尿病肾病
血栓素
前列环素
diabetes mellitus
diabetic nephropathy
thromboxane
prostacyclin
